Search clinical trials for: Glimepiride (HOE490)

Total 307 results

Ohio University
Western University of Health Sciences

Completed

INSPIRE Diabetes Study: Basal Bolus Insulin as Primary Treatment of Type 2 Diabetes (INSPIRE)

Type 2 Diabetes

United States
Merck Sharp & Dohme LLC

Completed

Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)

Diabetes Mellitus, Type 2
Sanofi

Completed

Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost. (ATOS)

Diabetes

Peru, Ukraine, Colombia, Egypt, India, Indonesia, Israel, Jordan, Kuwait, Lebanon, Mexico, Philippines, Russian Federation, Saudi Arabia, Singapore, Taiwan, Thailand, United Arab Emirates
Sanofi

Completed

Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1

Type 1 Diabetes Mellitus

Germany
Sanofi

Completed

Insulin Glulisine in Type 2 Diabetic Patients (Basal Plus)

Diabetes Mellitus, Type 2

Russian Federation, United States, United Kingdom
Sanofi

Completed

Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s) (Lixilan-O-AP)

Type 2 Diabetes Mellitus

China, Korea, Republic of, Malaysia, Taiwan
Seoul National University Hospital

Completed

Effects of Vildagliptine and Glimepiride on Glucose Variability

Diabetes Mellitus, Non-Insulin-Dependent

Korea, Republic of
ikfe-CRO GmbH
Novartis Pharmaceuticals; IKFE Institute for Clinical Research and Development

Unknown

Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy

Diabetes Mellitus Type II

Germany
Merck Sharp & Dohme LLC
Pfizer

Completed

A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).

Type 2 Diabetes Mellitus
Kurume University

Completed

Anti-Inflammatory Effects of Pioglitazone

Type 2 Diabetes Mellitus | Atherosclerosis | Impaired Glucose Tolerance

Japan
Sanofi

Completed

Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin (ARTEMIS-DM)

Type 2 Diabetes Mellitus

Argentina, Colombia, Egypt, Hong Kong, India, Indonesia, Lebanon, Malaysia, Peru, Philippines, Saudi Arabia, South Africa, Thailand, Turkey
Sanofi

Completed

Euglycemic Clamp Dose-response Study Comparing a New Insulin Glargine Formulation With Lantus®

Type 1 Diabetes Mellitus

Germany
Sanofi

Completed

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating Insulin (Reach-Control)

Diabetes Mellitus, Type 2

Germany, Spain, Brazil, France, Ireland, Romania, United Kingdom
Sanofi

Completed

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin (REGAIN CONTROL)

Diabetes Mellitus, Type 2

Italy, Ireland, Spain, Greece, Finland, Romania, Brazil, United Kingdom, France, Switzerland
Merck Sharp & Dohme LLC

Completed

Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)

Type 2 Diabetes Mellitus
Novartis Pharmaceuticals

Terminated

Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients (VARIABLE)

Type 2 Diabetes Mellitus
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Sanofi

Completed

Ease of Use and Safety of the New U300 Pen Injector in Insulin-Naïve Patients With T2DM

Diabetes Mellitus Type 2

Germany
University of Leicester
University Hospital Birmingham

Completed

Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan (Can Do)

Diabetes Mellitus, Type 2

United Kingdom
Janssen Research & Development, LLC

Completed

CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride

Diabetes Mellitus, Type 2

United States, Poland, Germany, Israel, Bulgaria, Costa Rica, India, Romania, Ukraine, Finland, Korea, Republic of, Canada, Philippines, Russian Federation, Argentina, Norway, Denmark, Slovakia, Mexico, Puerto Rico
Astellas Pharma Inc

Completed

A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Sulfonylurea in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

Japan
Sanofi

Terminated

Effectiveness and Safety of Two Approaches to the Management of Type 2 Diabetes Mellitus in Australian Primary Care (RELIANCE)

Diabetes Mellitus, Type 2

Australia
Brigham and Women's Hospital

Completed

Replication of the GRADE Diabetes Trial in Healthcare Claims Data

Diabetes

United States
Merck Sharp & Dohme LLC

Completed

A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)

Type 2 Diabetes Mellitus
University of Campania "Luigi Vanvitelli"

Unknown

Glycemic Durability After Metformin Failure (AMAZING)

Type 2 Diabetes

Italy
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes

Diabetes Mellitus, Type 2

France, Germany, Slovakia, Sweden, Ukraine, United Kingdom
Japan Association for Diabetes Education and Care
Merck Sharp & Dohme LLC

Completed

START-J: SiTAgliptin in eldeRly Trial in Japan (START-J)

Type 2 Diabetes

Japan
Boehringer Ingelheim
Eli Lilly and Company

Completed

Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)

Diabetes Mellitus, Type 2

Germany
Sanofi

Completed

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine (SORELLA1)

Type 1 Diabetes Mellitus

Japan, Spain, Germany, United States, France, Hungary, Poland, Russian Federation
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus (EDITION IV)

Type 1 Diabetes Mellitus

United States, Canada, Czech Republic, Denmark, Estonia, Finland, Hungary, Japan, Latvia, Netherlands, Puerto Rico, Romania, Sweden
Sanofi

Completed

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine (SORELLA2)

Type 2 Diabetes Mellitus

United States, Argentina, Chile, Colombia, Germany, Hungary, Italy, Korea, Republic of, Romania, Russian Federation, Spain, Turkey
Gilead Sciences

Completed

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States, Russian Federation, Thailand, Serbia, Poland, Hungary, Malaysia, South Africa, Ukraine, Czech Republic, Romania, Slovakia
Boehringer Ingelheim
Eli Lilly and Company

Completed

Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment

Diabetes Mellitus, Type 2

United States, Australia, Canada, Finland, Israel, Japan, New Zealand, Slovakia, Sweden
AstraZeneca
Bristol-Myers Squibb

Completed

Saxagliptin Compared to Glimepiride in Elderly Type 2 Diabetes Patients, With Inadequate Glycemic Control on Metformin (GENERATION)

Type 2 Diabetes Mellitus

Sweden, Italy, United Kingdom, Finland, Norway, Mexico, Austria, Denmark, Germany, Hungary, Greece, France, Spain
AstraZeneca
Bristol-Myers Squibb

Completed

Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients

Type 2 Diabetes

Czech Republic, Korea, Republic of, Hungary, Poland, Ukraine, Philippines, Thailand
Sanofi

Completed

Health Assessment, Patient Treatment Satisfaction and Quality-of-Life in Insulin-Naive Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

Germany
Merck Sharp & Dohme LLC
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)

Type 2 Diabetes Mellitus
Sanofi

Completed

Insulin Glargine Combination Therapies in Type II Diabetics (LAPTOP)

Diabetes Mellitus, Type 2

France, Germany, Netherlands, Spain, Sweden, Switzerland, United Kingdom, Finland, Italy, Austria
Sanofi

Completed

Evaluation of the Prandial Treatment Adjustment Effect Via Continuous Glucose Monitoring on Type 2 Diabetes Mellitus (DM) Patients Uncontrolled With a Basal Insulin or Premix Once a Day (SeLan)

Diabetes Mellitus, Type 2

Israel
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin

Type 1 Diabetes Mellitus

United States
Merck Sharp & Dohme LLC
Pfizer

Completed

Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)

Type 2 Diabetes Mellitus
Boehringer Ingelheim

Completed

A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate

Diabetes Mellitus, Type 2

United States, Canada, Mexico, Philippines, Romania, Russian Federation, Ukraine
Kansai Electric Power Hospital
Saiseikai Noe Hospital Osaka

Completed

Dietary Impacts on Glucose-lowering Effects of Sitagliptin in Type 2 Diabetes (DIET)

Diabetes Mellitus, Type 2

Japan
Dokkyo Medical University
Merck Sharp & Dohme LLC

Unknown

Effects of Sitaglpitin on Endothelial Function During the OGTT in T2DM

Type 2 Diabetes

Japan
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Mellitus on Basal Plus Mealtime Insulin (EDITION I)

Type 2 Diabetes Mellitus

United States, South Africa, Canada, Czechia, Estonia, Finland, France, Germany, Hungary, Latvia, Mexico, Netherlands, Romania
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy (EDITION II)

Type 2 Diabetes Mellitus

United States, Finland, South Africa, Canada, Mexico, Chile, Spain, Russian Federation, France, Germany, Hungary, Portugal, Romania
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy (EDITION III)

Type 2 Diabetes Mellitus

United States, Bulgaria, Canada, Czech Republic, Denmark, Estonia, Finland, Hungary, Japan, Latvia, Lithuania, Netherlands, Puerto Rico, Romania, Slovakia, Sweden
Chungbuk National University Hospital

Completed

Head-to-head Comparison of Empagliflozin and Dapagliflozin

Type2 Diabetes

Korea, Republic of
Theracos

Completed

Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin

Type2 Diabetes Mellitus

United States
The Catholic University of Korea
MSD Korea Ltd.

Unknown

Effect of Dipeptidyl Peptidase-IV Inhibitor and Sulfonylurea on Glucose Variability and Oxidative Stress

Type 2 Diabetes

Korea, Republic of

3

Subscribe